Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00856310 · ClinicalTrials.gov registry record · Phase 1
A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT00856310 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 56 participants.
The verdict
NCT00856310, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled single-dose study of the safety and tolerability of intravenously administered REGN475 in healthy volunteers. The primary objective of the study is to assess the safety and tolerability of REGN475. The secondary objectives are to characterize the pharmacokinetic and immunogenicity profiles of REGN475.
Interventions
- BIOLOGICAL REGN475 (SAR164877)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00856310
The ClinicalTrials.gov registry entry for NCT00856310 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which REGN475 (SAR164877) is the first listed.
NCT00856310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00856310 about?
NCT00856310 is a clinical study titled "A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects". This is a randomized, double-blind, placebo-controlled single-dose study of the safety and tolerability of intravenously administered REGN475 in healthy volunteers. The primary objective of the study is to assess the safety and tolerability of REGN475. The secondary objectives are to characterize th...
What is the current status of trial NCT00856310?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2009-02. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00856310?
The interventions under investigation include: REGN475 (SAR164877) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00856310?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.